(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Zentalis Pharmaceuticals's earnings in 2025 is -$162,783,000.On average, 11 Wall Street analysts forecast ZNTL's earnings for 2025 to be -$159,029,820, with the lowest ZNTL earnings forecast at -$238,378,818, and the highest ZNTL earnings forecast at -$137,093,428. On average, 11 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$151,960,545, with the lowest ZNTL earnings forecast at -$239,504,131, and the highest ZNTL earnings forecast at -$106,039,116.
In 2027, ZNTL is forecast to generate -$131,813,113 in earnings, with the lowest earnings forecast at -$156,230,964 and the highest earnings forecast at -$86,346,137.